DMT Shows Promise as Rapid-Acting Antidepressant in Clinical Trials
A recent clinical trial published in Nature Medicine suggests that intravenous administration of dimethyltryptamine (DMT) may offer a rapid and sustained reduction in symptoms of moderate to severe depression. The study, led by Professor David Ericho of Imperial College London, demonstrates a significant antidepressant effect even after a single 10-minute administration of the substance.
The Burden of Depression and Current Treatment Limitations
Major depressive disorder is a leading cause of disability worldwide, as recognized by the World Health Organization (WHO) in 2017. Current first-line treatments, selective serotonin reuptake inhibitors (SSRIs), are often ineffective or cause significant side effects for many patients. This has spurred research into alternative approaches, including psychedelic substances.
DMT: A Potential Breakthrough in Antidepressant Therapy
Hallucinogenic substances like psilocybin have garnered attention as potential antidepressants, but their extended treatment duration – often exceeding six hours – presents logistical challenges for clinical use. DMT, a naturally occurring substance that affects the serotonin system in the brain, offers a potential solution. Unlike psilocybin or lysergic acid diethylamide (LSD), DMT’s hallucinogenic effects are short-lived when administered intravenously, lasting only tens of minutes, thereby reducing treatment time, and costs.
Clinical Trial Design and Results
The clinical trial involved 34 patients diagnosed with moderate to severe depression who had not responded to conventional treatments. Participants were randomly assigned to receive either 21.5 mg of DMT or a placebo via a 10-minute intravenous infusion. Prior to administration, all participants received 90 minutes of psychological counseling, and during the infusion, two trained therapists were present, with patients wearing blindfolds and noise-blocking headphones.
Results indicated that the DMT group experienced a significantly greater reduction in depressive symptoms compared to the placebo group. Two weeks after administration, the DMT group showed an average reduction of 7.35 points on a standard depression test, a statistically significant difference comparable to the effects observed in psilocybin trials. This difference increased to 10.75 points after one week.
The antidepressant effects were sustained for up to three months, and at the six-month follow-up, 40% of participants maintained remission of depressive symptoms.
Safety and Side Effects
The study reported that most side effects were mild and did not significantly interfere with daily life. Common symptoms included pain at the injection site, nausea, and temporary anxiety. Importantly, no serious adverse events or suicidal ideation were reported. The incidence of side effects decreased with repeated administrations.
Future Directions and Considerations
This study represents the first placebo-controlled clinical trial to demonstrate the potential of DMT as a treatment for depression. Professor Ericho cautioned that the small sample size and limited racial diversity necessitate further research. He emphasized the need for larger, more diverse clinical trials and comparative studies with existing treatments to fully evaluate the efficacy and safety of DMT-assisted therapy.
doi.org/10.1038/s41591-025-04154-z